Numedicus is pleased to announce the licensing of two key pieces of intellectual property, and associated know-how, around the use of an existing glutamate modulator, for the treatment of Rett Syndrome and opiate-induced respiratory depression, to AMO Pharma. AMO Pharma Limited is a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, which has entered into a Development and License Agreement with Numedicus Limited, to advance the development of a glutamate modulator (AMO-04) and related compounds for the treatment of Rett Syndrome and certain breathing disorders. Led by Mike Snape, its CEO, AMO Pharma has built a pipeline with additional promising investigational therapies to treat rare diseases with significant areas of unmet need. Rett Syndrome is a devastating neurological condition for which there are currently no approved therapies, and it is intended to advance this programme rapidly into the clinic. AMO-04 is a unique drug with a long safety history that has shown significant promise as a potential treatment for Rett Syndrome based on screening by the Scout Program sponsored by Rettsyndrome.org and for certain breathing disorders based on research conducted by Numedicus collaborators. Numedicus was advised on the transaction by Shadow Lake Group Inc., a boutique life sciences advisory firm based in Toronto, Canada.